Betz Stephen F. 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Crinetics (CRNX) CSO Stephen F. Betz Sells 10,612 Shares
What Happened
- Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals (CRNX), sold a total of 10,612 shares in two open‑market transactions on March 16, 2026, generating aggregate proceeds of approximately $396,611. The sales were: 6,371 shares at a VWAP of $37.11 for $236,428 and 4,241 shares at a VWAP of $37.77 for $160,183. These dispositions were done pursuant to broker instructions under a Rule 10b5‑1 trading plan and were reported as tax‑withholding sales related to vested restricted stock units.
Key Details
- Transaction date: March 16, 2026 (Form 4 filed March 18, 2026 — filed timely)
- Sales: 6,371 shares @ VWAP $37.11 (price range $36.42–$37.38); 4,241 shares @ VWAP $37.77 (price range $37.42–$38.23)
- Total shares sold: 10,612; total proceeds ≈ $396,611
- Footnotes: F1 — sales effected to cover tax withholding on RSU vestings (grants from 2022–2025) and executed under a Rule 10b5‑1 plan; F2/F3 — VWAPs and intraday price ranges provided
- Shares owned after transaction: Not provided in the supplied data
Context
- These were routine disposition transactions to satisfy tax withholding on vested RSUs, not open-market purchases; such sales are commonly administrative and do not by themselves indicate insider sentiment. Transactions were executed under a pre-established 10b5‑1 plan, which schedules trades according to predetermined rules.
Insider Transaction Report
Form 4
Betz Stephen F.
Chief Scientific Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-03-16$37.11/sh−6,371$236,428→ 141,342 total - Sale
Common Stock
[F1][F3]2026-03-16$37.77/sh−4,241$160,183→ 137,101 total
Footnotes (3)
- [F1]Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
- [F3]The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
Signature
/s/ Tobin Schilke, as attorney-in-fact|2026-03-18